Elligo Health Research, an Austin, TX-based tech powered, healthcare-enabling research organization, raised $135m in Series E financing.
Morgan Stanley Expansion Capital and Ally Bridge Group, completed the investment in Elligo with participation from Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health. Morgan Stanley Expansion Capital Managing Director and General Partner, Melissa Daniels, has joined Elligo’s board.
The company intends to use the funds to acquire ClinEdge and invest further in the technology & data platform.
Led by CEO John Potthoff, Elligo is a healthcare-enabling research organization powered by its IntElligo Research Stack technology, which uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. It directly engages physicians and patients and accelerates the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.
combines proprietary data, technology, and services to support all trial designs — traditional, hybrid, and direct-to-patient — to expand and accelerate patient access to client trials. Its solutions address rising challenges faced by all key stakeholders in the clinical trial industry, including top pharma and biotech companies, contract research organizations, and research sites.